Evidence map›Paper›PMID 39066329›Full record

ArticleViruses2024

NTB-A and 2B4 Natural Killer Cell Receptors Modulate the Capacity of a Cocktail of Non-Neutralizing Antibodies and a Small CD4-Mimetic to Eliminate HIV-1-Infected Cells by Antibody-Dependent Cellular Cytotoxicity.

Lorie Marchitto, Alexandra Tauzin, Mehdi Benlarbi, Guillaume Beaudoin-Bussières, Katrina Dionne, Étienne Bélanger, Debashree Chatterjee, Catherine Bourassa, Halima Medjahed, Derek Yang and 5 more

Abstract read
In one paragraph

Article in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Lorie MarchittoCentre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
Alexandra TauzinCentre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.ORCID 0000-0001-9153-3600
Mehdi BenlarbiCentre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.ORCID 0000-0001-9966-3784
Guillaume Beaudoin-BussièresCentre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
Katrina DionneCentre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
Étienne BélangerCentre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
Debashree ChatterjeeCentre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
Catherine BourassaCentre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.ORCID 0000-0003-1805-8860
Halima MedjahedCentre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
Derek YangDepartment of Chemistry, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA 19104, USA.
Ta-Jung ChiuDepartment of Chemistry, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA 19104, USA.
Hung-Ching ChenDepartment of Chemistry, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0002-3359-5878
Amos B SmithDepartment of Chemistry, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA 19104, USA.
Jonathan RichardCentre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.ORCID 0000-0002-9015-9589
Andrés FinziCentre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.

Funding

ERASE HIV: Enterprise for Research and Advancements to Stop and Eradicate HIVUM1AI164562 · NIAID · EMORY UNIVERSITY · PI Deanna A Kulpa, Mirko Paiardini · 2021 to 2026
$30.0M
Exploring HIV-1 Env open conformations for therapeutic interventionR01AI150322 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Andres Finzi, James B Munro · 2020 to 2026
$4.2M
Assessing ADCC and Fc-mediated Protection against HIVR01AI148379 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI EVANS, DAVID T, FINZI, ANDRES · 2019 to 2023
$3.8M
Unlocking Envelope: A New Strategy for a Functional Cure Through Antibody-Dependent Cell-Mediated CytotoxicityR01AI129769 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI PAZGIER, MARZENA ELZBIETA · 2017 to 2021
$2.3M
CIHR 422148NIAID NIH HHS R01 AI129769NIAID NIH HHS R01 AI148379NIAID NIH HHS R01 AI150322NIAID NIH HHS UM1 AI164562
6 · The paper itself

Abstract

Natural Killer (NK) cells have the potential to eliminate HIV-1-infected cells by antibody-dependent cellular cytotoxicity (ADCC). NK cell activation is tightly regulated by the engagement of its inhibitory and activating receptors. The activating receptor CD16 drives ADCC upon binding to the Fc portion of antibodies; NK cell activation is further sustained by the co-engagement of activating receptors NTB-A and 2B4. During HIV-1 infection, Nef and Vpu accessory proteins contribute to ADCC escape by downregulating the ligands of NTB-A and 2B4. HIV-1 also evades ADCC by keeping its envelope glycoproteins (Env) in a "closed" conformation which effectively masks epitopes recognized by non-neutralizing antibodies (nnAbs) which are abundant in the plasma of people living with HIV. To achieve this, the virus uses its accessory proteins Nef and Vpu to downregulate the CD4 receptor, which otherwise interacts with Env and exposes the epitopes recognized by nnAbs. Small CD4-mimetic compounds (CD4mc) have the capacity to expose these epitopes, thus sensitizing infected cells to ADCC. Given the central role of NK cell co-activating receptors NTB-A and 2B4 in Fc-effector functions, we studied their contribution to CD4mc-mediated ADCC. Despite the fact that their ligands are partially downregulated by HIV-1, we found that both co-activating receptors significantly contribute to CD4mc sensitization of HIV-1-infected cells to ADCC.

Indexed as

Antibody-Dependent Cell CytotoxicityHIV-1HIV AntibodiesHIV InfectionsKiller Cells, NaturalSignaling Lymphocytic Activation Molecule FamilyAntibodies, NeutralizingCD4 AntigensHuman Immunodeficiency Virus ProteinsHumansnef Gene Products, Human Immunodeficiency VirusViral Regulatory and Accessory ProteinsViroporin ProteinsAntibodies, NeutralizingCD244 protein, humanCD4 AntigensHIV AntibodiesHuman Immunodeficiency Virus Proteinsnef Gene Products, Human Immunodeficiency VirusSignaling Lymphocytic Activation Molecule FamilyViral Regulatory and Accessory ProteinsViroporin Proteinsvpu protein, Human immunodeficiency virus 1ADCCCD4 mimeticsNK cell activating receptorsnnAbsplasma from PLWH

Identifiers

PMID39066329
PMCPMC11281563

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.